In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

Use of cystatin C and SGLT2 inhibitors were highlighted in the Kidney Disease: Improving Global Outcomes (KDIGO) organization ...

In a 2024 clinical practice guideline issued by the Kidney Disease: Improving Global Outcomes (KDIGO) organization, a ...

Improving Global Outcomes organization's updates to its 2024 guidelines expand SGLT2 inhibitor use and refine chronic kidney ...

Chronic Kidney Disease (CKD) indicates prolonged kidney damage over three months, often undetectable until significant harm ...

Chronic kidney disease is defined as either kidney damage or GFR <60 mL/min/1.73m 2 for ≥3 months. Kidney damage is defined as pathologic abnormalities or markers of damage, including ...

In 2021, several medical institutions began abandoning the race-based eGFR calculation in favor of race-neutral alternatives. The National Kidney Foundation and American Society of Nephrology Task ...

With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is ...

In a stable CKD population ... transdermal device that assesses GFR without the need for blood samples. The fluorescence-based test, developed by MediBeacon, demonstrated an exceptional ...

Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The Clinical Kidney Journal in February ...

You have permission to edit this article. Edit Close Activate Subscribe My Account Logout Login/Register ...